1. Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.
- Author
-
Muñoz-Casares, Francisco Cristóbal, Martín-Broto, Javier, Cascales-Campos, Pedro, Torres-Melero, Juan, López-Rojo, Irene, Gómez-Barbadillo, José, González-Bayón, Luis, Sebio, Ana, Serrano, César, Carvalhal, Sara, Abreu de Souza, Joaquim, Souza, Alexandre, Flores-Ayala, Guillermo, Palacios Fuenmayor, Luis José, Lopes-Bras, Raquel, González-López, José Antonio, Vasques, Hugo, and Asencio-Pascual, José Manuel
- Subjects
- *
CONSENSUS (Social sciences) , *SARCOMA , *DISEASE management , *THERMOTHERAPY , *CYTOREDUCTIVE surgery , *ADJUVANT chemotherapy , *PERITONEUM tumors , *SOFT tissue tumors - Abstract
Simple Summary: Peritoneal sarcomatosis has traditionally been characterized by a poor prognosis and few effective treatment options. Improving radical surgery procedures with high percentages of complete cytoreduction and limited morbidity in centers with considerable experience, together with new systemic treatments associated with evolutionary development in oncology, may modify this concept. The wide histological variability of soft tissue sarcomas that can cause peritoneal sarcomatosis prompts its evaluation and treatment by expert multidisciplinary teams. An updated review of the scientific evidence in this regard and the consensus regarding recommendations for the adequate management of this condition represent the main objective of this study. Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis. A multidisciplinary working group of experts in sarcomas and peritoneal oncological surgery established a series of recommendations based on current scientific evidence for the management of peritoneal sarcomatosis, taking into account the different histological subgroups of abdominopelvic sarcomas that can cause it depending on their origin: retroperitoneal sarcomas, uterine sarcomas, and visceral/peritoneal sarcomas of GIST (gastrointestinal stromal tumor) and non-GIST origin. This article shows the results of sarcoma experts' voting on the recommendations presented during the I Ibero-American Consensus on the Management of Peritoneal Sarcomatosis, which took place during the recent celebration of the III Hispanic-Portuguese Meeting for Updates on the Treatment of Sarcomas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF